Wednesday, 16 July 2014

cystic fibrosis symptoms, treatment, radiology, genetics and analysis Report: Opportunity Analysis and Forecasts to 2018

Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections; and obstructs pancreatic enzyme secretions that are essential for the body to break down and absorb nutrients. CF patients have a limited number of available treatment options and significant unmet needs still exist. Opportunities are significant for new therapies that will improve symptoms, change the course of this disease, as well as increase therapy options. The introduction of the first disease modifying therapy, Kalydeco (ivacaftor), by Vertex in 2012, paved the way for a new class of therapies known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators. On June 24, 2014, Vertex announced positive Phase III clinical trial data for lumacaftor in combination with Kalydeco in patients with CF who have two copies of the F508del mutation. This novel combination therapy of CFTR modulators has the potential to treat the underlying cause of the disease for approximately 50% of all CF patients and drive rapid growth in the CF market.

Overview of CF, including epidemiology, etiology, pathophysiology, symptoms and current treatment optionsAnnualized CF therapeutics market revenue, annual cost of therapies and forecasts for five years to 2018.Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the CF therapeutics market.Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including inhaled antibiotics, CFTR modulators and pancreatic enzyme products.Analysis of the current and future market competition in the US and five major EU CF therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.
Reasons to buy

Identify the unmet needs and remaining opportunities in the CF therapeutics market.Develop business strategies by understanding the trends shaping and driving the US and five major EU CF therapeutics market.Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.Assess the clinical and commercial viability of promising pipeline products.Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies.Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.Drive revenues by understanding the key trends, innovative products and technologies, market and segments likely to impact the US and five major EU CF therapeutics market in future.

Key Questions Answered

What are the pressing unmet needs and remaining opportunities in the CF market?What R&D strategies are drug developers pursuing in the CF therapeutics space?What is the significance of CFTR modulators in the CF market?What is the clinical and commercial positioning of key pipeline products in the CF market?What are the innovative early-stage treatment approaches in the CF market?
Key Findings

Rapid growth in the CF market is expected from 2012 to 2018.Emerging market players are employing diverse R&D strategies to gain entry in the CF market.A curative therapy is the most pressing unmet need in CF.Significant opportunities exist for novel disease modifying drugs.

To get all reports of this category visit:

Diagnostic X-ray Imaging - US, EU and APAC Analysis and Market Forecasts: MediPoint

An early diagnosis of disease is the foundation for increasing survival rates. Diagnostic X-ray imaging is the most widely used technique to achieve early detection and clinical assessment of adult and pediatric patients alike, making it a cornerstone of disease control. This report provides an analysis of the diagnostic X-ray imaging market in the US, the 5EU (France, Germany, Italy, Spain, and the UK), and some of the Asia-Pacific (APAC, EU and US) regions (Australia, China, India, and Japan), and identifies the unmet needs in this diagnostic X-ray systems market. This report also discusses physician attitudes towards the utilization and perception of different types of X-ray imaging techniques, and the future of diagnostic X-ray imaging in the face of rapid technological advancements and other advanced imaging modalities.

According to GlobalDatas estimates, GE Healthcare, Siemens, and Philips together accounted for over 40% of the market share within the APAC, EU and US diagnostic X-ray imaging market in 2012. This is mainly attributed to these companies geographical and product portfolio diversity. They are all a part of large conglomerates with robust financial resources to invest in inorganic growth and R&D; therefore, these players have a significant market share.

An overview of Diagnostic X-Ray Imaging, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.Annualized APAC, EU and US Diagnostic X-Ray Imaging market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.Investigation of current and future market competition for Diagnostic X-Ray Imaging.Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.Competitor assessment including device approval analysis and device sales forecasts.Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
Analysis of unmet needs within the market and opportunities for future players.Technology trends evaluation to assess strength of pipeline.An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.Company profiles including business description, financial overview and SWOT analysis.Coverage of key market players.Strategic assessment of the Diagnostic X-Ray Imaging sector through market impact analysis, future market scenario and company analysis.Direct quotes from Key Opinion Leaders (KOL) as well as doctors.

Reasons to buy

Understand the trends shaping and driving the APAC, EU and US Diagnostic X-Ray Imaging market.Realize device preferences of physicians who have performed the tests already.Access market sizing, forecasts and quantified growth opportunities in APAC, EU and US Diagnostic X-Ray Imaging market through 2018.Quantify candidate patient populations to better design product pricing & launch plans.Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.Perform benchmarking analysis of growth opportunities against currently marketed products.Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.Take a comprehensive look at the markets device pipeline and identify promising, paradigm-shifting products.Create an effective counter-strategy to gain a competitive advantage against those currently in the market.Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.Whats the next big thing in APAC, EU and US Diagnostic X-Ray Imaging market landscape? Identify, understand and capitalize.
Table of Content

1 Table of Contents
2 Introduction
3 Industry Overview
4 Unmet Needs Analysis
5 Market Opportunity Analysis
6 Market Drivers and Barriers
7 Competitive Assessment
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
11 Appendix